相关临床试验
3
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
1
33.3%
已完成
2
66.7%
暂无批准数据
- Over 4 million patients have already received faster lung cancer diagnoses or all-clears through AI-powered chest X-ray tools currently deployed in half of England's NHS trusts. - The UK government is investing £20 million to expand this proven AI technology to every NHS trust in England by 2029, with an additional £8.1 million for piloting six next-generation digital innovations. - Early data shows AI helps radiologists analyze scans in an average of 4 days compared to 8 days previously, enabling patients to begin treatment within the 62-day cancer waiting time standard. - Six new AI and digital technologies will be tested across 13 NHS sites targeting faster care for heart failure, stroke, lung cancer, lung infections, and tic disorders.
- Stanford University researchers successfully engineered gut bacteria to break down oxalate, a key component in kidney stone formation, demonstrating reduced oxalate levels in both animal models and human clinical trials. - The phase 1/2a trial involving 51 participants showed that all individuals receiving the engineered bacteria had lower oxalate levels compared to the placebo group after one month of treatment. - The engineered bacteria utilizes porphyran, a seaweed-derived nutrient rarely used by Western gut microbiomes, creating a controllable therapeutic niche with a built-in "kill switch" mechanism. - Despite promising results, challenges remain including persistent bacterial colonization in some participants and horizontal gene transfer events that may compromise therapeutic function.
